Takeda to Use Zinfandel TOMM40 Biomarker Assay for Alzheimer's Drug Study | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Takeda Pharmaceutical Company will use a biomarker assay developed by Zinfandel Pharmaceuticals as part of a clinical trial investigating the utility of Takeda's drug Actos in Alzheimer's disease, the companies said this week.

Under the terms of the agreement, Takeda has taken an exclusive, worldwide license for the use of Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."